CryoLife is one of the world’s contemporary medical device companies providing preserved human cardiac and vascular tissues, surgical adhesives and sealants, cardiac lasers and implantable end-stage renal disease access grafts for the repair of complex cardiac and vascular reconstruction surgeries. 
CryoLife using its proprietary SynerGraft technology processes the CryoValve SG pulmonary heart valve and CryoPatch SG pulmonary cardiac patch. CryoLife’s CardioGenesis specializes in the treatment of severe angina using a laser console system and fiber-optic handpieces to perform a surgical procedure known as Transmyocardial Revascularization (TMR). CryoLife markets the HeRO Graft, which provides vascular access for hemodialysis patients. CryoLife distributes PerClot, an absorbable powdered hemostat, in international markets. CryoLife’s BioFoam Surgical Matrix is CE marked in the European Community for use as an adjunct to hemostasis.

Show more
Type
Public
HQ
Kennesaw, US
Founded
1984
Size (employees)
665 (est)
CryoLife was founded in 1984 and is headquartered in Kennesaw, US
Report incorrect company information

Key People/Management at CryoLife

Thomas F. Ackerman

Thomas F. Ackerman

Member of the Board

CryoLife Office Locations

CryoLife has offices in Paris, Singapore, Freiburg im Breisgau, Kennesaw and in 1 other location
Kennesaw, US (HQ)
1655 Roberts Blvd
Paris, FR
52 Rue de la Victoire
Freiburg im Breisgau, DE
19 Engelbergerstraße
Singapore, SG
1 Marina Blvd
Guildford, GB
Old Portsmouth Rd
Show all (5)
Report incorrect company information

CryoLife Financials and Metrics

CryoLife Financials

CryoLife's revenue was reported to be $189.70 m in FY, 2017
USD

Revenue (FY, 2017)

189.7 m

Net income (FY, 2017)

3.7 m

EBIT (FY, 2017)

8 m

Market capitalization (20-Apr-2018)

796 m

Cash (31-Dec-2017)

40 m

EV

975 m
CryoLife's current market capitalization is $796 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

140.8 m144.6 m145.9 m180.4 m189.7 m

Revenue growth, %

3%1%24%

R&D expense

13.4 m19.5 m

Operating expense total

13.4 m120.7 m
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Revenue

43 m47.1 b45.3 m45.1 m47.8 m44 m

R&D expense

2.6 m3.3 b3.7 m4.1 m4.7 m4.3 m

Operating expense total

28.9 m25.7 b24.3 m27 m28.1 m29 m

EBIT

6.7 m4.6 b5.5 m2.5 m4.8 m829 k
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

37.6 m33.4 m37.6 m56.6 m40 m

Accounts Receivable

136.7 m

Inventories

9.8 m12.7 m14.6 m26.3 m46.7 m

Current Assets

106.3 m106 m109.7 m147.2 m179.3 m
Quarterly
USDQ1, 2014Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Cash

32.8 m44.8 m46.9 m54.1 m58.9 m52.5 m54.2 m

Inventories

11.5 m25.3 m25.4 m25.5 m25.8 m26.5 m27.8 m

Current Assets

105.9 m129.2 m135.8 m142.1 m149.2 m152.2 m155.6 m

PP&E

12 m16.5 m16.4 m17.2 m20.2 m20.7 m20.6 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

16.2 m7.3 m4 b10.8 m3.7 m

Depreciation and Amortization

5.8 m6 m5.9 b8.4 m9.7 m

Inventories

Accounts Payable

Quarterly
USDQ1, 2014Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Net Income

1.1 m2.5 m4.9 m7.9 m2.2 m5.4 m6.7 m

Depreciation and Amortization

1.5 m1.9 m4.1 m6.2 m2.2 m4.4 m6.7 m

Cash From Investing Activities

(1.7 m)(67.2 m)(69.2 m)(71.1 m)(1.2 m)(3.6 m)(4.6 m)

Dividends Paid

(772 k)(850 k)(1.7 m)(2.6 m)
USDY, 2017

EV/EBIT

122.3 x

EV/CFO

90.3 x

EV/FCF

233.8 x

Revenue/Employee

285.3 k

Financial Leverage

2.1 x
Show all financial metrics
Report incorrect company information